The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan.


Journal

Journal of gastroenterology
ISSN: 1435-5922
Titre abrégé: J Gastroenterol
Pays: Japan
ID NLM: 9430794

Informations de publication

Date de publication:
02 2021
Historique:
received: 26 08 2020
accepted: 31 10 2020
pubmed: 22 11 2020
medline: 15 12 2021
entrez: 21 11 2020
Statut: ppublish

Résumé

We recently reported the real-world changes in the etiologies of liver cirrhosis (LC) based on nationwide survey data and assessed the etiologies of LC with hepatocellular carcinoma (HCC). Fifty-five participants from 68 institutions provided data on 23,637 patients with HCC-complicated LC. The changing trends in etiologies were assessed. We further analyzed the data from 29 hospitals that provided the annual number of newly identified HCC-complicated LC patients from 2008 to 2016 (N = 9362) without any missing years and assessed the transition in the real number of newly identified HCC-complicated LC cases. In the overall cohort, hepatitis C virus (HCV) infection (60.3%) and hepatitis B virus (HBV) infection (12.9%) were the leading and third-most common causes of HCC-complicated LC in Japan, respectively. HCV infection was found to be the leading cause throughout Japan. The rate of viral hepatitis-related HCC decreased from 85.3 to 64.4%. Among non-viral etiologies, notable increases were observed in nonalcoholic steatohepatitis (NASH)-related HCC (from 1.5 to 7.2%) and alcoholic liver disease (ALD)-related HCC (from 8.5 to 18.6%). Regarding the real number of newly diagnosed patients, the number of patients with viral hepatitis-related HCC decreased, while the number of patients with non-viral HCC, particularly NASH-related HCC, increased. Viral hepatitis has remained the main cause of HCC in Japan. However, the decrease in viral hepatitis-related HCC, particularly HCV-related HCC highly contributed to the etiological changes. In addition, the increased incidence of non-viral HCC, particularly NASH-related HCC, was involved in the changing etiologies of HCC-complicated LC in Japan.

Sections du résumé

BACKGROUND
We recently reported the real-world changes in the etiologies of liver cirrhosis (LC) based on nationwide survey data and assessed the etiologies of LC with hepatocellular carcinoma (HCC).
METHODS
Fifty-five participants from 68 institutions provided data on 23,637 patients with HCC-complicated LC. The changing trends in etiologies were assessed. We further analyzed the data from 29 hospitals that provided the annual number of newly identified HCC-complicated LC patients from 2008 to 2016 (N = 9362) without any missing years and assessed the transition in the real number of newly identified HCC-complicated LC cases.
RESULTS
In the overall cohort, hepatitis C virus (HCV) infection (60.3%) and hepatitis B virus (HBV) infection (12.9%) were the leading and third-most common causes of HCC-complicated LC in Japan, respectively. HCV infection was found to be the leading cause throughout Japan. The rate of viral hepatitis-related HCC decreased from 85.3 to 64.4%. Among non-viral etiologies, notable increases were observed in nonalcoholic steatohepatitis (NASH)-related HCC (from 1.5 to 7.2%) and alcoholic liver disease (ALD)-related HCC (from 8.5 to 18.6%). Regarding the real number of newly diagnosed patients, the number of patients with viral hepatitis-related HCC decreased, while the number of patients with non-viral HCC, particularly NASH-related HCC, increased.
CONCLUSIONS
Viral hepatitis has remained the main cause of HCC in Japan. However, the decrease in viral hepatitis-related HCC, particularly HCV-related HCC highly contributed to the etiological changes. In addition, the increased incidence of non-viral HCC, particularly NASH-related HCC, was involved in the changing etiologies of HCC-complicated LC in Japan.

Identifiants

pubmed: 33219410
doi: 10.1007/s00535-020-01748-x
pii: 10.1007/s00535-020-01748-x
pmc: PMC7862502
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

158-167

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Références

Hepatol Int. 2019 Sep;13(5):587-598
pubmed: 31463665
Hepatol Res. 2020 Aug;50(8):892-923
pubmed: 32343469
Hepatol Res. 2020 Jan;50(1):15-46
pubmed: 31655492
J Gastroenterol. 2019 Sep;54(9):829-836
pubmed: 31161311
Hepatol Res. 2019 Oct;49(10):1114-1120
pubmed: 31077527
J Gastroenterol. 2010;45(1):86-94
pubmed: 19789837
Clin Gastroenterol Hepatol. 2019 Mar;17(4):748-755.e3
pubmed: 29908364
Hepatol Res. 2012 Apr;42(4):368-75
pubmed: 22151896
Gastroenterology. 2019 Jan;156(2):477-491.e1
pubmed: 30367835
JAMA. 2018 May 1;319(17):1802-1813
pubmed: 29715359
J Gastroenterol. 2011 Oct;46(10):1230-7
pubmed: 21748549
Lancet. 2019 Oct 19;394(10207):1451-1466
pubmed: 31631857
Oncology. 2002;62 Suppl 1:8-17
pubmed: 11868791
Hepatol Res. 2015 Jan;45(1):59-74
pubmed: 24965914
Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589-604
pubmed: 31439937
Hepatol Res. 2020 Jul;50(7):791-816
pubmed: 32343477
Lancet Gastroenterol Hepatol. 2020 Feb;5(2):167-228
pubmed: 31852635
Hepatol Res. 2019 Sep;49(9):990-1002
pubmed: 31364248
Dig Liver Dis. 2020 Jan;52(1):98-101
pubmed: 31582326
J Gastroenterol Hepatol. 2020 May;35(5):855-861
pubmed: 31609495
J Gastroenterol. 2020 Mar;55(3):353-362
pubmed: 31768801
Infection. 2020 Feb;48(1):7-17
pubmed: 31347138
Hepatol Res. 2017 May;47(6):487-496
pubmed: 28326651
J Gastroenterol. 2019 Jan;54(1):87-95
pubmed: 30203225
J Gastroenterol. 2019 Apr;54(4):367-376
pubmed: 30498904

Auteurs

Hirayuki Enomoto (H)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.

Yoshiyuki Ueno (Y)

Department of Gastroenterology, Faculty of Medicine, Yamagata University, Yamagata, Japan.

Yoichi Hiasa (Y)

Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.

Hiroki Nishikawa (H)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
Center for Clinical Research and Education, Hyogo College of Medicine, Nishinomiya, Japan.

Shuhei Hige (S)

Department of Hepatology, Sapporo Kosei General Hospital, Sapporo, Japan.

Yasuhiro Takikawa (Y)

Division of Hepatology, Department of Internal Medicine, Iwate Medical University, Morioka, Japan.

Makiko Taniai (M)

Internal Medicine, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan.

Toru Ishikawa (T)

Department of Gastroenterology and Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Japan.

Kohichiroh Yasui (K)

Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Akinobu Takaki (A)

Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Koichi Takaguchi (K)

Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.

Akio Ido (A)

Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.

Masayuki Kurosaki (M)

Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Musashino, Japan.

Tatsuya Kanto (T)

Hepatitis Information Center, The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Tokyo, Japan.

Shuhei Nishiguchi (S)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan. nishiguchi@heartfull.or.jp.
Department of Gastroenterology, Kano General Hospital, 7-5-15, Tenjin-bashi, Kita-ku, Osaka, 531-0041, Japan. nishiguchi@heartfull.or.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH